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Use of Terbinafine in the Treatment Protocol of Intestinal Cryptococcus
neoformans in a Dog
Abstract
A 2.5 yr old sexually intact male vizsla was admitted to the Iowa State University Veterinary Teaching Hospital
for persistent diarrhea, weight loss, and panhypoproteinemia. Examination revealed an emaciated condition
and melena. Two masses were palpated in the cranial abdomen. Hematology and serum biochemistry
exhibited a regenerative anemia and confirmed the presence of panhypoproteinemia, suggestive of a protein-
losing eneteropathy. Distinct areas of thickened intestinal wall and enlarged mesenteric lymph nodes were
found on abdominal ultrasound. Cytology from those nodes showed the presence of suspected Cryptococcus
spp., and infection was confirmed utilizing a cryptococcal antigen titer. Medical therapy with lipid-complexed
amphotericin B and fluconazole was unsuccessful. Two surgical procedures were performed to remove the
affected areas of intestine and lymph nodes, but the disease persisted as evidenced by a persistently elevated
cryptococcal antigen titer. Terbinafine was prescribed, which resulted in complete resolution of clinical signs
and a steadily decreasing cryptococcal antigen titer. Very few cases of intestinal cryptococcosis have been
reported. In this case, infection resulted in a protein-losing enteropathy. In addition, this article describes the
use of terbinafine in the treatment of intestinal cryptococcal infection in the dog, which has not been
previously reported.
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CASE REPORTS
Use of Terbinaﬁne in the Treatment Protocol of
Intestinal Cryptococcus neoformans in a Dog
Gavin L. Olsen, DVM*y, Krysta L. Deitz, MS, DVM, DACVIM, Heather A. Flaherty, DVM, DACVP,
Shawn R. Lockhart, PhD, DABMM, Steven F. Hurst, MS, Joseph S. Haynes, DVM, PhD, DACVP
ABSTRACT
A 2.5 yr old sexually intact male vizsla was admitted to the Iowa State University Veterinary Teaching Hospital for persistent
diarrhea, weight loss, and panhypoproteinemia. Examination revealed an emaciated condition and melena. Two masses were
palpated in the cranial abdomen. Hematology and serum biochemistry exhibited a regenerative anemia and conﬁrmed the
presence of panhypoproteinemia, suggestive of a protein-losing eneteropathy. Distinct areas of thickened intestinal wall
and enlarged mesenteric lymph nodes were found on abdominal ultrasound. Cytology from those nodes showed the presence
of suspected Cryptococcus spp., and infection was conﬁrmed utilizing a cryptococcal antigen titer. Medical therapy with
lipid-complexed amphotericin B and ﬂuconazole was unsuccessful. Two surgical procedures were performed to remove the
affected areas of intestine and lymph nodes, but the disease persisted as evidenced by a persistently elevated cryptococcal
antigen titer. Terbinaﬁne was prescribed, which resulted in complete resolution of clinical signs and a steadily decreasing
cryptococcal antigen titer. Very few cases of intestinal cryptococcosis have been reported. In this case, infection resulted in
a protein-losing enteropathy. In addition, this article describes the use of terbinaﬁne in the treatment of intestinal cryptococcal
infection in the dog, which has not been previously reported. (J Am Anim Hosp Assoc 2012; 48:216–220. DOI 10.5326/JAAHA-MS-
5813)
Introduction
Cryptococcus neoformans and C. gatii are fungal organisms that
infect many domesticated species, as well as humans. It is thought
that infection is acquired environmentally, following inhalation
of basidiospores. This yeast is not generally considered trans-
missible from one infected animal to either another animal or to a
human.1
The primary means of diagnosis of cryptococcosis is iden-
tiﬁcation of the organism on aspirate or histopathology. An en-
capsulated basophilic organism with narrow-based budding is
characteristic for Cryptococcus spp.1 If the disease is suspected but
no organisms are identiﬁed, fungal culture of the affected areas
may yield diagnostic results. The organism has also been reported
on fecal cytology.2 Otherwise, the latex agglutination test is used
for identifying the capsular antigen in serum.3 Although that test
has been proven to be sensitive, it has also been shown that the
antigen can persist in the serum for an extended period of time
after clinical disease has subsided.4 One additional method of
identiﬁcation is through DNA sequencing, as was the case with
this patient.
Cryptococcosis has been documented in the nasal cavity,
central nervous system, optic nerve, cutis, bone, lymph nodes, and
(uncommonly) in the gastrointestinal tract of various species.1 The
case presented here describes a unique presentation of protein-
losing enteropathy due to infection with C. neoformans located
primarily within the small intestine and local lymph nodes, as well
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as utilization of a novel therapy, terbinaﬁne, in the treatment
protocol that resolved the enteropathy.
Case Report
A 2.5 yr old male vizsla weighing 14 kg was referred to the
emergency service of the Iowa State University Veterinary Teaching
Hospital with a 4–5 mo history of weight loss and small bowel
diarrhea. Initially, empirical therapy with metronidazole (12.5
mg/kg per os [PO] q 12 hr), cefpodoxime (10 mg/kg PO q 24 hr),
and a bland diet had been prescribed by the referring veterinarian
to alleviate the diarrhea. No improvement was noted. Repeated
serum biochemical analyses performed over the 3 mo period prior
to presentation showed only a panhypoproteinemia. Total protein
was 4.9 g/dL (reference range, 5.0–7.4 g/dL) and albumin was 2.0
g/dL (reference range, 2.7–4.4 g/dL). Vomiting and melena de-
veloped 1 mo prior to referral. At that time, 1 mg/kg prednisone
PO q 24 hr was prescribed. The metronidazole was continued,
and sucralfate (1 g PO q 8 hr) was also added to the treatment
regimen.
Upon presentation to the Internal Medicine Service of the
Iowa State University Veterinary Teaching Hospital, the patient was
quiet, alert, and responsive. Physical exam revealed severe ema-
ciation (body condition score was grade 1/9). Mucous membranes
were pale with a normal capillary reﬁll time. There were no ab-
normalities on abdominal palpation, and peripheral lymph nodes
were not enlarged. The rest of the physical examwas unremarkable.
The initial complete blood count demonstrated a leukocytosis
(25.873103/mL; reference range, 6.0–17.03103/mL) characterized
by a mature neutrophilia (19.403103/mL; reference range, 3.0–
11.43103/mL) and a monocytosis (3.623103/mL; reference range,
0.15–1.353103mL). A macrocytic, hypochromic, regenerative ane-
mia was also noted. The red blood cell count was 2.213106/mL
(reference range, 5.50–8.503106/mL), hematocrit was 17.3% (ref-
erence range, 37.0–55.0%), hemoglobin was 5.4 g/dL (reference
range, 12.0–18.0 g/dL), corrected reticulocyte count was 3.8%
(reference range, ,1.0%) mean corpuscular volume was 78.6 fL
(reference range, 60.0–77.0 fL), and mean corpuscular hemoglobin
concentration was 31.4 g/dL (reference range, 32.0–36.0 g/dL).
Serum biochemistry abnormalities included hypokalemia (3.5
mEq/L; reference range, 3.9–5.3 mEq/L), hypocalcemia (8.6 mg/dL;
reference range, 9.2–11.2 mg/dL), panhypoproteinemia (total
protein was 3.3 g/dL; reference range, 5.2–7.1 g/dL and albumin
was 1.6 g/dL; reference range, 3.2–4.3 g/dL), hypocholesterolemia
(108.0 mg/dL; reference range, 140–270 mg/dL), and an elevated
blood lactate (10.3 mmol/L; reference range, ,2.0 mmol/L). Col-
loid oncotic pressure was decreased (7.1 mmHg; reference range,
20–26 mmHg). Fecal ﬂotation did not identify any ova, and an
enzyme-linked immunosorbent assay for Giardia antigen was
negative. Urinalysis uncovered no signiﬁcant abnormalities. A
neurologic exam and a dilated ophthalmic exam (performed by
an ophthalmologist) were unremarkable.
Due to the panhypoproteinemia, decreased oncotic pressure,
and worsening anemia, the patient was hospitalized and received
packed red blood cellsa, plasmab, and 6% hetastarchc transfusions.
Abdominal radiographs were performed, which revealed de-
creased abdominal detail likely due to a combination of decreased
fat for contrast and abdominal effusion. Thoracic radiographs
were performed to investigate tachypnea. A mild amount of
pleural effusion was noted, whereas the pulmonary parenchyma
appeared normal. A cranial abdominal mass was also discovered
upon repeated palpation. Abdominal ultrasound revealed two
areas of thickened intestine (approximately 12 mm wall thickness;
reference range, # 2.6mm) with loss of normal wall layering.
Additionally, two masses (both measuring approximately 80 mm3
30 mm in size) were present in the midabdominal region, which
were presumed to be mesenteric lymph nodes based on their
location, shape, and echogenicity. Cytologic examination of
ultrasound-guided ﬁne-needle aspirates obtained from those two
masses displayed moderate numbers of red blood cells and
neutrophils, with numerous extracellular, round-to-oval organisms
ranging in size from 4 mm to 20 mm in diameter with a large clear
capsule, a basophilic center, and rare narrow-based budding.
These organisms were most consistent with Cryptococcus spp.
(Figure 1).
FIGURE 1 Photomicrograph of a ﬁne-needle aspirate of the mes-
enteric lymph node demonstrating neutrophilic inﬂammation (mostly
degenerate neutrophils and nuclear streaming) with multiple yeast-like
organisms surrounded by a clear capsule, including one exhibiting
narrow-based budding. Wright’s stain, original magniﬁcation 3100.
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Cryptococcal antigen titers via latex agglutination were
submitted and ﬂuconazoled (5 mg/kg PO q 12 hr) was initiated
along with IV lipid-complexed amphotericin B (AMB)e. The ﬁrst
dose of AMB was 0.5 mg/kg, with subsequent doses incrementally
increased to a maximum of 1.5 mg/kg. In total, 11 treatments
were administered q 48 hr, resulting in a ﬁnal cumulative dose of
14 mg/kg. Doses of AMB were given over a 30 min period and
were preceded and followed with 4 hr of diuresis. Serial urinalyses
and serum biochemistries were monitored throughout the AMB
treatment period to monitor for any signs of renal damage (i.e., casts,
increasing urea nitrogen or creatinine). The patient’s renal values
and urinary concentrating ability remained stable throughout the
treatment period. At completion of the AMB treatment, the pan-
hypoproteinemia persisted (total protein was 3.7 g/dL and albumin
was 1.4 g/dL).
The original cryptococcal antigen titer was positive at the
1:420 dilution. After 2 wk of treatment with ﬂuconazole and AMB,
antigen titer was 1:462. While receiving antifungal treatment, the
dog’s attitude improved, along with appetite, fecal consistency,
and body condition, with a weight gain of 1 kg. However, 2 wk
after the AMB was discontinued, the patient began losing weight,
his attitude declined, and melena recurred. Repeat ultrasono-
graphic evaluation of the abdomen revealed that the presumed
lymph nodes, as well as the thickened intestines, had not changed
in either size or appearance. Surgical intervention was recom-
mended at this time. Analysis of a complete blood count and
serum biochemistry indicated a worsening anemia (packed cell
volume was 12%) and decreasing total solids (periodic measure-
ment of total solids had revealed improvement to a peak of 4.8 g/dL,
but subsequently decreased to 3.6 g/dL). Albumin was 1.5 g/dL.
Cross-matched-compatible packed red blood cell and plasma
transfusions were administered immediately prior to surgery. Two
mesenteric lymph nodes and approximately 60 cm of jejunum (and
associated mesentery) were removed (Figures 2A, B). The section of
jejunum that was removed was orad to the ileocecocolic junction
and aborad to the duodenum. Recovery from surgery was un-
eventful. Following surgery (within 24 hr), AMB was initiated.
The cumulative dose was 16.0 mg/kg, with monitoring of renal
values and urinalysis as previously described. After the AMB
treatment was completed, ﬂuconazole was reinitiated at the
original dose. In addition, histologic examination of the excised
intestinal and mesenteric lymph nodes conﬁrmed the presence
of fungal organisms consistent with Cryptococcus spp. Fungal
cultures were submitted to multiple institutions, but yielded no
growth upon multiple attempts.
One month after completion of the AMB, the patient was
bright, alert, and responsive. A moderate weight increase was noted
during the AMB treatment period (body weight increased from
15.9 kg to 20.4 kg and body condition score increased to grade 4/9).
Cryptococcal antigen titers were rechecked and had markedly
decreased to 1:69. Fluconazole was prescribed for an additional
6 mo with scheduled rechecks of the antigen titer q 3 mo. At the
time of the ﬁrst recheck, the antigen titer was 1:124, but by 5 mo
postsurgically, the patient had lost weight and was vomiting.
Ultrasound revealed enlarged mesenteric lymph nodes and mul-
tiple areas of thickened intestine, similar to ﬁndings previous
to the surgery. Additionally, there appeared to be an intestinal
stricture, which was considered to be the cause of the patient’s
clinical signs. A second surgery was therefore performed to re-
move the strictured intestine (measuring approximately 10 cm
in length), effectively alleviating the obstruction. Histopathology
of the strictured area of intestine was similar to the previous
surgery, with fungal organisms and granulomatous inﬂammation
predominating. Terbinaﬁnef (30 mg/kg PO q 24 hr) was initiated
in place of ﬂuconazole. This medication was prescribed in-
deﬁnitely to be re-evaluated based upon clinical response and
FIGURE 2 A: Intraoperative photograph showing the encircling nature of the fungal growth in the wall of the jejunum (arrow heads).
B: Photograph of the resected intestine. Note the encircling lesions (arrowheads) with associated lymphatic involvement (arrows).
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cryptococcal antigen titers. After initiation of terbinaﬁne, the
patient improved continually. No clinical relapses were noted, and
the cryptococcal antigen titer decreased steadily. At the time this
report was written, the patient was doing well, maintaining both
weight and appetite. A negative cryptococcal antigen titer was
ultimately achieved. Two years after initiating terbinaﬁne, no
additional surgeries were required. Total protein and albumin
returned to normal values (6.5 g/dL and 3.6 g/dL, respectively)
within 1.5 mo after initiating terbinaﬁne and remained normal
for the duration of the follow-up period. Serial ultrasound ex-
aminations performed q 6 mo after the second surgery did not
identify any additional areas of thickened intestine, and mon-
itoring of mesenteric lymph nodes indicated resolution of the
lymphadenomegaly by approximately 2 yr after initiation of
terbinaﬁne.
Although cryptococcal antigen titers conﬁrmed the presence
of the organism, failure of fungal growth precluded deﬁnitive
identiﬁcation of the organism. For this reason, polymerase chain
reaction identiﬁcation of the organism from parafﬁn-embedded
intestinal tissue was attempted as previously described.5 Primers
ITS3/IT4, which amplify the ITS2 region of the 18S rDNA, were
used for ampliﬁcation. A single 376 base pair product was am-
pliﬁed and sequenced in both directions using the ampliﬁcation
primers. A Basic Local Alignment Search Tool using the Genbank
database gave a 100% match to multiple isolates of C. neoformans,
including strain ATCC MYA-4565. There were no acceptable
matches to other species, conﬁrming C. neoformans as the caus-
ative agent.
Discussion
The patient in this case presented with a long history of weight
loss associated with nonresolving diarrhea that had recently es-
calated to include vomiting and melena. Additionally, the dog had
long-standing panhypoproteinemia and anemia. To the authors’
knowledge, this is the ﬁrst reported case of panhypoproteinemia
with resolution following treatment of intestinal cryptococcosis.
Furthermore, the authors of this report did not ﬁnd any other
reports describing terbinaﬁne for the treatment regimen for
cryptococcosis, emphasizing that this was a novel approach to the
disease.
A previous report described cryptococcal infection of the
gastric mucosa of a dog, which closely resembled a gastric mass in
appearance.6 Few other reports have described intra-abdominal
infections as the sole location of the disease.7,8 The present case is
one of very few cases that the authors are aware of in which the
primary route of infection appeared to be gastrointestinal, in-
volving the mesenteric lymph nodes and circumferential intestinal
lesions. Reports in the human literature of primary intestinal
cryptococcal disease appear to be limited to immunocompromised
individuals, and lesions were noted in multiple different areas
of the intestinal tract.9–11 Medical therapy was attempted ﬁrst in
this case to provide a less-invasive treatment of the disease.
However, after medical treatment failed to resolve the lesions,
surgical therapy was pursued followed by a novel medical therapy,
terbinaﬁne.
There are occasional reports of the development of resistance
to ﬂuconazole during long-term therapy for cryptococcosis in
humans.12 This may explain why the lesions in the case described
herein did not respond favorably to treatment with ﬂuconazole,
despite its excellent penetration of the gastrotinestinal tract.
However, once terbinaﬁne was initiated, cryptococcal antigen
titers dropped dramatically and the patient remained stable. Al-
though response to treatment could not be deﬁnitively related to
the patient’s improvement (surgery coincided with the com-
mencement of terbinaﬁne), a previous surgery did not result in
sustained improvement as was noted with the terbinaﬁne. After
beginning terbinaﬁne, no additional intestinal lesions developed
and lymphadenopathy resolved. Although it is possible that the
lack of efﬁcacy of ﬂuconazole stems from the thickened intestine
and the inability of the drug to penetrate the intestinal tissue and
that surgical removal of the lesions and continuation of the ﬂu-
conazole might have resulted in clinical remission, it also seems
apparent that treatment with terbinaﬁne resulted in resolution of
clinical signs and decreasing antigen titers.
Terbinaﬁne has been documented to enter the central nervous
system of rats.13 In addition, terbinaﬁne has been investigated in
the treatment of rabbit coccidioidal meningitis, but it was not
found in any appreciable concentration in the cerebrospinal ﬂuid.14
Additionally, there are a few reports indicating good in vitro activity
of terbinaﬁne against C. neoformans.15,16 Uptake into the central
nervous system appears to be species-dependent and needs to be
further investigated for both humans and dogs as an inexpensive
treatment alternative for cryptococcal meningitis, a disease often
noted affecting immunocompromised individuals. There is little
information in the literature regarding terbinaﬁne in the treat-
ment protocol of canines with intestinal fungal diseases. Two
recent cases were reported out of Brazil. One of those indicated
success, whereas the other reported failure with a treatment pro-
tocol that used terbinaﬁne.17,18 Another recent study investigated
the pharmacokinetics of terbinaﬁne in canines and revealed that
plasma concentrations high enough to combat systemic fungal
diseases can be achieved.19
Side effects of terbinaﬁne have not routinely been encoun-
tered in the canine species, but mild gastrointestinal upset can
Treatment of C. neoformans with Terbinaﬁne
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occur. In addition to the gastrointestinal upset, idiosyncratic events
including liver failure and dermatologic abnormalities have been
reported in humans.20 No adverse effects were encountered in this
patient during treatment with terbinaﬁne. Terbinaﬁne may be-
come an acceptable alternative treatment of veterinary crypto-
coccal infections due to its efﬁcacy and cost (as little as $12/mo for
the patient reported herein), but further investigation is needed.
Although insufﬁcient data are currently available to recommend
terbinaﬁne as a ﬁrst-line agent, use in cases where primary ther-
apy has failed to yield a response may prove beneﬁcial.
Conclusion
The patient described in this report had an unusual presentation
of C. neoformans, leading to a protein-losing enteropathy. Novel
therapy with terbinaﬁne likely aided in the recovery of this pa-
tient. Additional studies investigating the efﬁcacy of terbinaﬁne
for cryptococcosis of different organ systems are necessary.
The ﬁndings and conclusions of this article are those of the authors
and do not necessarily represent the views of the Centers for Dis-
ease Control and Prevention.
FOOTNOTES
a Packed red blood cell transfusion; Iowa State University College of
Veterinary Medicine Non-Resident Blood Donor Program, Ames, IA
b Plasma transfusion; Iowa State University College of Veterinary
Medicine Non-Resident Blood Donor Program, Ames, IA
c 6% hetastarch in 0.9% sodium chloride injection; Hospira Inc., Lake
Forrest, IL
d Fluconazole 100 mg tablets; IVAX Pharmaceuticals Inc., Miami, FL
e Abelcet 100 mg vial (amphotericin B lipid complex injection);
Enzon Pharmaceuticals Inc., Bridgewater, NJ
f Terbinaﬁne 250 mg tablets; Northstar Rx LLC, Memphis, TN
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